Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyronaridine PK/PD in Induced Malaria
NCT05287893Phase 1Completed
- Sponsor
- Medicines for Malaria Venture
- Start
- Apr 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pyronaridine in Falciparum malaria (PF) (4 arms), sponsored by Medicines for Malaria Venture. Primary endpoints: Maximum Effect, Half maximal effective concentration and 4 more. Started Apr 2022; status: completed.
02
Drugs
pyronaridine
03
Conditions
Falciparum malaria (PF)
Beyond the preview
Go deeper on NCT05287893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05287893.